Literature DB >> 2525256

Phosphorylation-dependent activation of the adenovirus-inducible E2F transcription factor in a cell-free system.

S Bagchi1, P Raychaudhuri, J R Nevins.   

Abstract

Adenovirus infection induces a large increase in the DNA binding activity of a cellular transcription factor that is utilized by the viral E2 promoter and termed E2F. Using cell-free extracts, we have developed an assay for the in vitro activation of DNA binding activity of E2F. E2F activity is undetectable in HeLa extracts but upon incubation with a fraction from adenovirus-infected cells, there is an ATP-dependent increase in E2F DNA binding activity. This increase does not occur using an equivalent fraction from dl312 (E1A-)-infected cells. Incubation of E2F with phosphatase inactivates E2F binding activity. Incubation of the phosphatase-inactivated E2F with an infected cell fraction restores E2F activity as does incubation with a known protein kinase. In contrast, incubation with an extract from mock-infected cells does not restore activity. We conclude that the DNA binding activity of E2F is regulated by phosphorylation in an E1A-dependent manner.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525256      PMCID: PMC287267          DOI: 10.1073/pnas.86.12.4352

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Activation of gene expression by adenovirus and herpesvirus regulatory genes acting in trans and by a cis-acting adenovirus enhancer element.

Authors:  M J Imperiale; L T Feldman; J R Nevins
Journal:  Cell       Date:  1983-11       Impact factor: 41.582

2.  Cis-acting induction of adenovirus transcription.

Authors:  R B Gaynor; A J Berk
Journal:  Cell       Date:  1983-07       Impact factor: 41.582

3.  Definition and mapping of adenovirus 2 nuclear transcription.

Authors:  J R Nevins
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

4.  Mechanism of activation of early viral transcription by the adenovirus E1A gene product.

Authors:  J R Nevins
Journal:  Cell       Date:  1981-10       Impact factor: 41.582

5.  Pre-early adenovirus 5 gene product regulates synthesis of early viral messenger RNAs.

Authors:  A J Berk; F Lee; T Harrison; J Williams; P A Sharp
Journal:  Cell       Date:  1979-08       Impact factor: 41.582

6.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

Authors:  J D Dignam; R M Lebovitz; R G Roeder
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

7.  The adenovirus-2 EIIa early gene promoter: sequences required for efficient in vitro and in vivo transcription.

Authors:  R Elkaim; C Goding; C Kédinger
Journal:  Nucleic Acids Res       Date:  1983-10-25       Impact factor: 16.971

8.  Expression of early adenovirus genes requires a viral encoded acidic polypeptide.

Authors:  R P Ricciardi; R L Jones; C L Cepko; P A Sharp; B E Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

9.  Regulation of the primary expression of the early adenovirus transcription units.

Authors:  J R Nevins; H S Ginsberg; J M Blanchard; M C Wilson; J E Darnell
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

10.  Adenovirus stimulation of transcription by RNA polymerase III: evidence for an E1A-dependent increase in transcription factor IIIC concentration.

Authors:  S Yoshinaga; N Dean; M Han; A J Berk
Journal:  EMBO J       Date:  1986-02       Impact factor: 11.598

View more
  43 in total

1.  Adenovirus E4orf4 protein reduces phosphorylation of c-Fos and E1A proteins while simultaneously reducing the level of AP-1.

Authors:  U Müller; T Kleinberger; T Shenk
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

2.  A DNA element that regulates expression of an endogenous retrovirus during F9 cell differentiation is E1A dependent.

Authors:  B T Lamb; K Satyamoorthy; D Solter; A Basu; M Q Xu; R Weinmann; C C Howe
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

3.  Interaction of a common factor with ATF, Sp1, or TATAA promoter elements is required for these sequences to mediate transactivation by the adenoviral oncogene E1a.

Authors:  S J Weintraub; D C Dean
Journal:  Mol Cell Biol       Date:  1992-02       Impact factor: 4.272

4.  A transcriptionally active form of TFIIIC is modified in poliovirus-infected HeLa cells.

Authors:  M E Clark; A Dasgupta
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

5.  The adenovirus E4 gene, in addition to the E1A gene, is important for trans-activation of E2 transcription and for E2F activation.

Authors:  R Reichel; S D Neill; I Kovesdi; M C Simon; P Raychaudhuri; J R Nevins
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

6.  A purified adenovirus 289-amino-acid E1A protein activates RNA polymerase III transcription in vitro and alters transcription factor TFIIIC.

Authors:  S Datta; C J Soong; D M Wang; M L Harter
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

7.  trans-dominant mutants of E1A provide genetic evidence that the zinc finger of the trans-activating domain binds a transcription factor.

Authors:  L C Webster; R P Ricciardi
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

8.  Phosphorylation sites of the E2 transcriptional regulatory proteins of bovine papillomavirus type 1.

Authors:  A A McBride; J B Bolen; P M Howley
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

9.  Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation.

Authors:  M Xu; K A Sheppard; C Y Peng; A S Yee; H Piwnica-Worms
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

10.  Interferons and interleukin-6 suppress the DNA-binding activity of E2F in growth-sensitive hematopoietic cells.

Authors:  D Melamed; N Tiefenbrun; A Yarden; A Kimchi
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.